Drug Interactions on QTc in Exploratory COVID-19 Treatment: Implications for Arrhythmia Risk
Severely ill COVID-19 patients with comorbidities are at increased risk of serious arrhythmias due to potential drug interactions affecting QTc interval, highlighting the importance of careful monitoring and pharmacological management to minimize cardiac complications in this population.
December 2020
Update on Penicillin Allergy: Epidemiology, Pathophysiology, Diagnosis, and Management
Comprehensive update on penicillin allergy, covering epidemiological trends, underlying pathophysiology, diagnostic approaches, and management strategies to improve patient care and antibiotic stewardship.
September 2020
Raloxifene Not Associated with Increased Cardiovascular Risk in Women
Contrary to previous concerns, a study conducted at the University of California, San Diego, suggests that raloxifene, a drug used to treat osteoporosis, does not appear to elevate the risk of heart problems in women with cardiovascular disease. This finding provides reassurance regarding the drug's safety profile.
November 2002
Experimental Drug Reduces Weight in Obese Mice
Researchers at Johns Hopkins University report that an experimental substance called C75 has demonstrated appetite-suppressing effects and led to rapid weight loss in obese mice. While promising, further research is needed to evaluate its safety and efficacy in humans.
November 2002
Thalidomide Shows Promise in Treating Acute Myeloid Leukemia
Despite its controversial history, thalidomide has emerged as a potential treatment for acute myeloid leukemia, demonstrating efficacy in certain patient populations. This highlights the importance of reevaluating existing drugs for new therapeutic applications.
November 2002
